Search Result
Results for "
IgG1-κ
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Cancer
|
|
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 [1] .
|
-
-
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) [1] .
|
-
-
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Cancer
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis [1] .
|
-
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis [1].
|
-
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) [1] .
|
-
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells [1].
|
-
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
|
-
-
- HY-P990038
-
-
-
- HY-P99864
-
|
ZTS-00521505
|
Interleukin Related
|
Others
|
|
Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
|
-
-
- HY-P99104
-
|
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [1] .
|
-
-
- HY-P990057
-
-
-
- HY-P990024
-
-
-
- HY-P99699
-
|
MHAB5553A; RG70026
|
Influenza Virus
|
Infection
|
|
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody [1].
|
-
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Cancer
|
|
Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) [1].
|
-
-
- HY-P9909
-
-
-
- HY-P990036
-
|
|
IFNAR
|
Infection
|
|
Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) [1].
|
-
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) [1].
|
-
-
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) [1] .
|
-
-
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a chimeric humanized IgG1κ antibody targeting the mouse signaling regulatory protein CD27.
|
-
-
- HY-P99615
-
|
SB 209763; RSHZ19
|
RSV
|
Infection
|
|
Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV [1] .
|
-
-
- HY-P990035
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, derived from mice [1].
|
-
-
- HY-P99368
-
|
MCS110; Anti-Human B7-H3
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis [1] .
|
-
-
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
-
-
- HY-P990041
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer [1].
|
-
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research [1].
|
-
-
- HY-P990052
-
|
MAD-0004J08
|
SARS-CoV
|
Infection
|
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain [1].
|
-
-
- HY-P99040
-
|
JNJ-61610588
|
PD-1/PD-L1
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity [1].
|
-
-
- HY-P99310
-
|
RG4934; Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis [1].
|
-
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research [1].
|
-
-
- HY-P99181
-
|
CPI-006
|
CD73
|
Infection
Inflammation/Immunology
|
|
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells [1].
|
-
-
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) [1].
|
-
-
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies [1].
|
-
-
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities [1].
|
-
-
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells [1].
|
-
-
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity [1].
|
-
-
- HY-P99313
-
|
Anti-Human NGcGM3 Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research [1].
|
-
-
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1] .
|
-
-
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) [1].
|
-
-
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection [1] .
|
-
-
- HY-P99655
-
|
KB004
|
Ephrin Receptor
Apoptosis
|
Cancer
|
|
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 + cells and improves pulmonary fibrosis [1] .
|
-
-
- HY-P99740
-
|
|
CD276/B7-H3
|
Cancer
|
|
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) [1].
|
-
-
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [1] .
|
-
-
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) [1] .
|
-
-
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) [1].
|
-
-
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody [1].
|
-
-
- HY-P99925
-
|
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively [1].
|
-
-
- HY-P990037
-
|
|
CD38
|
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity [1].
|
-
-
- HY-P990086
-
|
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity [1].
|
-
-
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC [1].
|
-
-
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody [1].
|
-
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor [1].
|
-
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections [1] .
|
-
- HY-P99137
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) [1] .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Cancer
|
|
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 [1] .
|
-
- HY-P99105
-
-
- HY-P9990
-
|
BIIB059
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study [1] .
|
-
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) [1] .
|
-
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Cancer
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis [1] .
|
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis [1].
|
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) [1] .
|
-
- HY-P99899
-
-
- HY-P99898
-
-
- HY-P99979
-
-
- HY-P99977
-
-
- HY-P99980
-
-
- HY-P99896
-
-
- HY-P99869
-
|
|
Inhibitory Antibodies
|
Others
|
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells [1].
|
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells [1].
|
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
|
-
- HY-P990038
-
-
- HY-P99864
-
|
ZTS-00521505
|
Interleukin Related
|
Others
|
|
Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
|
-
- HY-P99104
-
|
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [1] .
|
-
- HY-P990057
-
-
- HY-P99800
-
-
- HY-P99828
-
|
PF-06523435; hu24
|
Inhibitory Antibodies
|
Others
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells [1].
|
-
- HY-P990024
-
-
- HY-P990056
-
-
- HY-P990085
-
-
- HY-P99778
-
|
MORAb-004
|
Inhibitory Antibodies
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer [1].
|
-
- HY-P99447
-
-
- HY-P99699
-
|
MHAB5553A; RG70026
|
Influenza Virus
|
Infection
|
|
Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody [1].
|
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Cancer
|
|
Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) [1].
|
-
- HY-P99880
-
|
LFB-R593
|
Inhibitory Antibodies
|
Others
|
|
Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells [1].
|
-
- HY-P990053
-
-
- HY-P9909
-
-
- HY-P990036
-
|
|
IFNAR
|
Infection
|
|
Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) [1].
|
-
- HY-P990043
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Iluzanebart is a human IgG1κ antibody targeting TREM2, a triggering receptor expressed on myeloid cells [1].
|
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) [1].
|
-
- HY-P99654
-
|
INT-001
|
Inhibitory Antibodies
|
Cancer
|
|
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) [1] .
|
-
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) [1] .
|
-
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a chimeric humanized IgG1κ antibody targeting the mouse signaling regulatory protein CD27.
|
-
- HY-P99615
-
|
SB 209763; RSHZ19
|
RSV
|
Infection
|
|
Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV [1] .
|
-
- HY-P990035
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, derived from mice [1].
|
-
- HY-P990044
-
-
- HY-P99368
-
|
MCS110; Anti-Human B7-H3
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis [1] .
|
-
- HY-P990019
-
-
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
-
- HY-P99674
-
|
GEN-3009
|
Inhibitory Antibodies
|
Cancer
|
|
Ivicentamab (GEN-3009) is an IgG1κ anti-CD37 humanized monoclonal antibody. Ivicentamab can be used for cancer research [1].
|
-
- HY-P99658
-
|
PRX-003
|
Inhibitory Antibodies
|
Cancer
|
|
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent [1].
|
-
- HY-P990051
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Delpacibart is a humanized, mouse IgG1κ antibody targeting TFRC. TFRC is the most important membrane protein that regulates intracellular iron transport processes [1].
|
-
- HY-P990041
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer [1].
|
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research [1].
|
-
- HY-P99571
-
|
INH-H 2002
|
Inhibitory Antibodies
|
Infection
|
|
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections [1] .
|
- HY-P990052
-
|
MAD-0004J08
|
SARS-CoV
|
Infection
|
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain [1].
|
- HY-P99040
-
|
JNJ-61610588
|
PD-1/PD-L1
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity [1].
|
- HY-P99310
-
|
RG4934; Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis [1].
|
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research [1].
|
- HY-P99181
-
|
CPI-006
|
CD73
|
Infection
Inflammation/Immunology
|
|
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells [1].
|
- HY-P9966
-
|
MGA271
|
Inhibitory Antibodies
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators [1].
|
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) [1].
|
- HY-P99591
-
|
AS1402; huHMFG-1
|
Inhibitory Antibodies
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer [1].
|
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies [1].
|
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities [1].
|
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells [1].
|
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity [1].
|
- HY-P99313
-
|
Anti-Human NGcGM3 Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research [1].
|
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1] .
|
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) [1].
|
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection [1] .
|
- HY-P99655
-
|
KB004
|
Ephrin Receptor
Apoptosis
|
Cancer
|
|
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 + cells and improves pulmonary fibrosis [1] .
|
- HY-P99306
-
|
DS 1024; Sym 004
|
Inhibitory Antibodies
|
Cancer
|
|
Modotuximab (Anti-Human EGFR Recombinant Antibody) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab contains a portion of Futuximab that binds to two independent, non-overlapping epitopes on EGFR. Modotuximab promotes cross-linking of EGFR on the cell surface and promotes EGFR cellular internalization and degradation. Modotuximab has antitumor activity in vivo [1].
|
- HY-P99740
-
|
|
CD276/B7-H3
|
Cancer
|
|
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) [1].
|
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease [1] .
|
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) [1] .
|
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) [1].
|
- HY-P99001
-
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody [1].
|
- HY-P99925
-
|
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively [1].
|
- HY-P990037
-
|
|
CD38
|
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity [1].
|
- HY-P990086
-
|
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity [1].
|
- HY-P990022
-
|
DS-6016A
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research [1].
|
- HY-P990245
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse FAP Antibody (73.3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse FAP.
|
- HY-P990155
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse TIGIT.
|
- HY-P990137
-
- HY-P990289
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD172a Antibody (P84) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD172a.
|
- HY-P990257
-
- HY-P990274
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Canine CD34 Antibody (1H6) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine CD34.
|
- HY-P990261
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD83 Antibody (Michel-17) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD83.
|
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC [1].
|
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody [1].
|
- HY-P990283
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD22.
|
- HY-P990239
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Mouse GRP78 Antibody (N88) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse GRP78.
|
- HY-P990250
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse DKK3.
|
- HY-P990126
-
- HY-P990216
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-25 Antibody (2C3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-25.
|
- HY-P990121
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-4 Antibody (11B11) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-4.
|
- HY-P990265
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD69 Antibody (CD69.2.2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD69.
|
- HY-P990160
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat TCR alpha/beta.
|
- HY-P990136
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to monkey/human CD28.
|
- HY-P990213
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse/human IL-5.
|
- HY-P990113
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat TCR gamma/delta Antibody (V65) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat TCR gamma/delta.
|
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor [1].
|
- HY-P990222
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-17A Antibody (17F3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-17A.
|
- HY-P990119
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse Kappa Immunoglobulin Light Chain.
|
- HY-P990241
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse GITR (D265A) Antibody (DTA-1-CP027) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse GITR.
|
- HY-P990251
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.
|
- HY-P990248
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse E-Cadherin/CD324.
|
- HY-P990117
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human Osteopontin/SPP1.
|
- HY-P990212
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-6.
|
- HY-P990217
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-23 p19.
|
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections [1] .
|
- HY-P990132
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
|
- HY-P990115
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse OX40/CD134.
|
- HY-P990258
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CLEC9A/CD370 Antibody (7H11) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CLEC9A/CD370.
|
- HY-P990166
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse PSGL-1/CD162.
|
- HY-P990178
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse NKG2D/CD314.
|
- HY-P990235
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3-CP044) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse ICOSL/CD275.
|
- HY-P990162
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse T15 VH and T15 VL regions of IgM.
|
- HY-P99806
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research [1] .
|
- HY-P990128
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat CD80/B7-1.
|
- HY-P990173
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.
|
- HY-P990294
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD106/VCAM-1.
|
- HY-P990204
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W-CP013) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse LAG-3.
|
- HY-P990202
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human LRP1/CD91.
|
- HY-P990228
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-10R/CD210.
|
- HY-P990270
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1-CP032) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD40L/CD154.
|
- HY-P990279
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD276/B7-H3.
|
- HY-P990221
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-17F.
|
- HY-P990114
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine PD-L1/B7-H1.
|
- HY-P99145A
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2?-CP168) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
|
- HY-P990172
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2?-CP001) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
|
- HY-P99137
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) [1] .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
